NRX-101, A RAPID-ACTING ANTI-DEPRESSANT, DOES NOT CAUSE NEUROTOXICITY FOLLOWING KETAMINE ADMINISTRATION IN PRECLINICAL MODELS

Abstract

ABSTRACTBackgroundNMDA (N-Methyl-D aspartate) receptor antagonists have gained increasing attention as rapid-acting antidepressants. However, their use has been limited by potential neurotoxicity (Olney Lesions) and recent FDA guidance requires demonstration of safety on histologic parameters prior to initiation of human studies. D-cycloserine is a mixed NMDA agonist/antagonist awarded Breakthrough Therapy Designation and currently in clinical trials for the treatment of bipolar depression with suicidal ideation. The current study was designed to investigate the neurologic safety profile of D-cycloserine by itself and in combination with ketamine and lurasidone.MethodsSprague Dawley female rats (n=106) were randomly divided into 7 study groups. Ketamine was administered via tail vein infusion. D-cycloserine and lurasidone were administered via oral gavage in escalating doses to a maximum of 2000 mg/kg DCS. To ascertain toxicity, dose escalation with three different doses of D-cycloserine/lurasidone was given in combination with ketamine. MK-801, a known neurotoxic NMDA antagonist, was administered as a positive control. Brain tissue was sectioned and stained with H&E and Fluorojade stains.ResultsNo fatalities were observed in any group. No microscopic abnormalities were found in the brain of animal subjects given ketamine, ketamine followed by DCS/lurasidone, or DCS/lurasidone alone. Neuronal necrosis, as expected, was seen in the MK-801 positive control group.ConclusionNRX-101, a fixed-dose combination of D-cycloserine/lurasidone, when administered with or without prior infusion of IV ketamine was tolerated and did not induce neurotoxicity, even at maximum-tolerated doses of D-cycloserine.HIGHLIGHTSNRX-101, a fixed dose combination of D-cycloserine and lurasidone does not exhibit histologic neurotoxicity, even at maximum-tolerated doses